Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
about
Effects of Tumor Necrosis Factor-α on Podocyte Expression of Monocyte Chemoattractant Protein-1 and in Diabetic NephropathyMiRNA-29c regulates the expression of inflammatory cytokines in diabetic nephropathy by targeting tristetraprolin.Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathyInflammatory cytokines in diabetic nephropathy.Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal InjuryArginase inhibition: a new treatment for preventing progression of established diabetic nephropathyInvolvement of the NLRC4-Inflammasome in Diabetic Nephropathy.Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seqExpression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammationRole of the monocyte chemoattractant protein-1/C-C chemokine receptor 2 signaling pathway in transient receptor potential vanilloid type 1 ablation-induced renal injury in salt-sensitive hypertension.Meprin A impairs epithelial barrier function, enhances monocyte migration, and cleaves the tight junction protein occludin.Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanismMacrophages directly mediate diabetic renal injury.Emerging roles of hematopoietic cells in the pathobiology of diabetic complications.Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Fetuin-A aggravates lipotoxicity in podocytes via interleukin-1 signaling.Developing Treatments for Chronic Kidney Disease in the 21st Century.The NLRP3 inflammasome in kidney disease and autoimmunity.The next generation of therapeutics for chronic kidney diseaseInflammasome Activation in Chronic Glomerular Diseases.Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice.Monocyte-Derived Dendritic Cells Impair Early Graft Function Following Allogeneic Islet Transplantation.Integrative Analysis of miRNA and mRNA Expression Profiles in Calcium Oxalate Nephrolithiasis Rat Model.Chemokines in homeostasis and diseases.Overexpression of heart-type fatty acid binding protein enhances fatty acid-induced podocyte injury.Distinct roles of arginases 1 and 2 in diabetic nephropathy.Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy.Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease.
P2860
Q28080888-71C86437-B1AE-4A20-8AEC-6AF70B2E5074Q33725787-91693E2F-936A-4EFE-9E45-9BED1199EC78Q33825220-95BC14DE-327A-4E8E-BE39-70577F32ACCCQ34836376-13CE9EAD-593A-4755-920B-24A507A59E47Q35133177-B47905B3-433D-476B-8FDE-F9A8980EB33AQ35710293-B4F757C8-3E7A-425F-96A7-BE4828CAA04DQ36017619-378FE740-3EC8-4621-85A4-1577203E6F7DQ36153911-99039557-2601-4FAA-878C-A99E7627E670Q36195357-B451A430-77B2-48B5-942F-FFC3AAE10022Q37051472-48C4AAF9-AFF6-462F-B1F1-500EE3FC2100Q37071386-38E8CACB-CD73-4CCC-A352-934108C35F2CQ37142513-E431CC68-07F1-49A5-854A-44DA986766C7Q37142636-5F083337-881B-422D-9B8E-08EAB9A8AEADQ37198831-C5192CDC-14F5-419A-9427-F720C16D52DEQ37440181-78213B02-0AC6-4627-9432-0608DE9E8813Q37684896-9B1A1C46-DE73-4CD3-B4BB-352AC421BEC6Q38087529-0CDD1503-8616-424C-8A2F-82A3D1953F76Q38255902-E44DE583-F780-4145-B5D2-567A36C3C7E2Q38758052-28B4BE18-5E3F-4FF4-8064-77461D0F1948Q38781550-5DA41911-48B0-43D4-AC39-78F8E887E244Q38787339-32EC3640-05D8-4FF4-B7B0-04E021C3CAE7Q38845590-A187B01F-B803-43B2-B80B-0FEE35694444Q38931056-9B5E278B-4D37-4B27-BE3B-B35D0CD2736BQ38936622-BEA31F91-5821-4DFB-B033-9048D021086BQ40271425-2957FDF2-0B33-481D-8102-498F86AC312BQ41559116-84852A3E-DAD6-4791-9957-CE9F40F5E149Q45232179-41931542-B509-427D-ACB0-FFF0BBBBDE8CQ47161249-173CB158-39D2-4049-A44E-60B217AD7A3AQ48119451-4D04CA7F-05BC-49E4-96BA-C1C8143A0873Q49634148-8F4F9283-E2D8-4A4F-BE12-37F57C3A070CQ50053918-F3AC7D66-91F1-4146-A4C4-2C83EE96F010Q51033386-82C8A8CF-AFDF-427A-AD3D-076E5A380A88Q51287276-8B1D4341-3DC1-4C8B-9A0B-372AB4281F98Q53296448-F00D396D-4312-4D10-B51D-882720E7B43AQ55312504-F9F29BBB-09F9-4C6A-A8DB-550A3201F559
P2860
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@ast
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@en
type
label
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@ast
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@en
prefLabel
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@ast
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@en
P2093
P2860
P1476
Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury
@en
P2093
Alaa S Awad
Gilbert R Kinsey
Konstantine Khutsishvili
W Kline Bolton
P2860
P304
P356
10.1152/AJPRENAL.00332.2011
P577
2011-08-31T00:00:00Z